위암 치료제 시장 : 치료법별, 용도별, 유통경로별, 지역별

Stomach Cancer Drugs Market is estimated to be valued at USD 5,600 Mn in 2026 and is expected to reach USD 9,100 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Key features of the study

• This report provides in-depth analysis of the stomach cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global stomach cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
• The global stomach cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stomach cancer drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• Therapy Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy Trastuzumab
  • Trastuzumab
• Application Insights (Revenue, USD Mn, 2026 - 2033)
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Endoscopic Surgery
  • Surgical Suite
  • Dental Surgery
  • Others
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Kuhnil Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Merck KGaA
  • AstraZeneca Plc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Ono Pharmaceutical Co. Ltd.
  • Bristol-Myers Squibb (BMS)
  • Jiangsu HengRui Medicine Co. Ltd.
  • Gilead Science Inc.
  • Celgene Corporation
  • Taiho Pharmaceutical
  • Boston Biomedical Inc.
  • Merck & Co.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Stomach Cancer Drugs Market, By Therapy Type
  • Global Stomach Cancer Drugs Market, By Application
  • Global Stomach Cancer Drugs Market, By Distribution Channel
  • Global Stomach Cancer Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Stomach Cancer Drugs Market, By Therapy Type, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Nucleoside Metabolic Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Anthracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• VEGF Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• HER2 Receptor Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Car T Cell Therapy Trastuzumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Trastuzumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Stomach Cancer Drugs Market, By Application, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adenocarcinomas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Gastrointestinal Stromal Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Carcinoid Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Stomach Cancer Drugs Market, By Distribution Channel, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Stomach Cancer Drugs Market, By Region, 2020 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Value (USD Mn)
  • Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kuhnil Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Holdings Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ono Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb (BMS)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Jiangsu HengRui Medicine Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Science Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celgene Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taiho Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boston Biomedical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us